glp-1 kidney cancer GLP-1s tied to lower risk for 10 types of compared with insulin in type 2 diabetes GLP-1 drugs may reduce the

GLP-1 & GIP: It retains the appetite suppression, gastric slowing, and insulin-boosting properties of Tirzepatide

Taking CagriSema achieved 23.0% body weight loss per the efficacy estimand versus 25.5% for tirzepatide

Front Pharmacol (2021) 12:781856

It can be caused by various factors, including diabetes, surgeries, infections, and certain medications

We recognize that weight management can be challenging, and thats why we stay up to date on the latest advancements, including GLP-1 (glucagon-like peptide-1) agonists, which have shown promise in weight loss

But what if decades of nutrition science have been quietly proving otherwise